Proxy Results (Form 8-K)

On August 19, 2026, Sonoma Pharmaceuticals, Inc. (the "Company") held an adjourned special meeting of stockholders (the "Special Meeting"), pursuant to a definitive proxy statement, filed with the Securities and Exchange Commission on May 5, 2026. On April 28, 2026, the record date for the Special Meeting, there were 3,473,554 shares of common stock of the Company entitled to be voted at the Special Meeting. The presence in person or by proxy of the holders of 1,157,852 shares, or one-third of the shares of common stock issued and outstanding and entitled to vote, represented in person or by proxy, was required to constitute a quorum. A quorum was not present at the adjourned Special Meeting. The Chairman of the Special Meeting cancelled the Special Meeting, and the Company will not solicit additional proxies.